AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca and GKS shares have legs, but the weight loss titans will dominate, says investment bank
AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) remain among Berenberg's top picks in the pharmaceuticals sector, with the broker reaffirming its 'buy' rating on both stocks. The former carries a target price of £140, while the valuation for stock in the latter is £16.
Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead
The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities broadly remain down for the year.
AstraZeneca CEO on its $2.5 billion investment in Beijing hub
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in the Chinese capital.
Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot
Pascal Soriot, CEO of British pharmaceutical giant AstraZeneca, discusses the company's $2.5 billion investment in a new China research and development center.
Watch CNBC's full interview with Pascal Soriot, AstraZeneca CEO
Pascal Soriot, CEO, AstraZeneca discusses the company's $2.5 billion investment in its new China research and development centre.
British pharma giant AstraZeneca to invest $2.5 billion in new China hub
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China. Outside the Macclesfield factory of AstraZeneca.
AstraZeneca investing $2.5 bln in China as drugmaker seeks to recover from scandals
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw Astrazeneca (AZN) settling at $76.32, representing a -0.97% change from its previous close.
AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer
The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based on ADRIATIC study data.
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies
AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.
AstraZeneca Buys EsoBiotec for Up to $1 Billion
The deal includes the Belgian biotech's vivo cell-therapy platform, which modifies immune cells within the patient's body, potentially increasing access to treatment and reducing costs.
AstraZeneca pays $1bn for biotech that may 'transform cell therapy'
AstraZeneca PLC (LSE:AZN) has agreed to pay up to $1 billion to buy EsoBiotec, a Belgian company that has made clinical breakthroughs in cell therapy, where immune cells are engineered directly within the patient's body. The FTSE 100 giant will pay $425 million when the deal closes, which is expected before June, plus up to a further $575 million based on development and regulatory milestones.
